Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference Call and Webcast to Follow WASHINGTON , Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, November 2, 2022, during which management will discuss the third quarter 2022 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales. The company recently planted long-term growth via the OliPas partnership for ASO development.

Vanda: VPO-227 Advancement Signals More Upsides

WASHINGTON , Oct. 21, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227 for the treatment of cholera. While the incidence of cholera in the U.S. is low, cholera is a widespread infectious diarrheal disease with estimated 1.4 to 4 million cases worldwide, resulting in 21,000 to 143,000 deaths annually.1 Many of these deaths occur in children, as diarrheal diseases are the second leading cause of death globally among children under 5 years of age.2 Cholera remains a major public health challenge and recognized unmet medical need despite decades-long public health efforts.

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

Vanda Pharmaceuticals is a stellar growth stock trading near its cash position. Despite the latest revenue trend aberration, Vanda is still set to post significant sales increase for Fiscal 2022.

Vanda Pharmaceuticals: What The Recent Partnership Entails

WASHINGTON , Sept. 29, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) (KOSDAQ: 24460) today announced that they have entered into a research and development collaboration agreement to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass' proprietary modified peptide nucleic acids.

Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics

WASHINGTON , Sept. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C.

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

WASHINGTON , Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) to treat jet lag disorder.

VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER

Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos - President & Chief Executive Officer Kevin Moran - Senior Vice President & Chief Financial Officer Conference Call Participants Chris Howerton - Jefferies Operator Thank you for standing by, and welcome to the Q2 2022 Vanda Pharmaceuticals, Inc. Earnings Call.

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2022 Results - Earnings Call Transcript

Q2 2022 total revenues were $64.4 million Total revenues in the first six months of 2022 were $124.6 million Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON , Aug. 3, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022. "During the second quarter we made significant progress towards commercializing our products and improving access to HETLIOZ® for patients with Non-24," said Mihael H.

Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

Conference Call and Webcast to Follow WASHINGTON , July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, August 3, 2022, during which management will discuss the second quarter 2022 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

Wilmington, Delaware--(Newsfile Corp. - June 30, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-vanda-pharmaceuticals-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vanda Pharmaceuticals Inc.

WASHINGTON , June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New York City on Thursday, June 9, 2022. A corporate presentation is scheduled for 3:30 p.m.

Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference

WASHINGTON , May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022. The following scientific posters will be presented: June 7, 2022 Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsPoster Session Presentation Time: 5:15 PM – 7:15 PM ET Title: "Enrichment of RAI1 genetic aberrations associated with sleep disturbances in SMS, in Autism Spectrum Disorder"  Poster Number: 007 Title: "A 10-week observational research study in individuals with delayed sleep-wake phase disorder (DSWPD) symptoms"Poster Number: 028 Title: "A novel missense variant in Melanopsin associates with delayed sleep phenotype: whole-genome sequencing study"  Poster Number: 285 For more information on SLEEP 2022, please refer to https://www.sleepmeeting.org/.

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

WASHINGTON , May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022. The following will be presented: May 21, 2022 Presentation Title: "THE ROLE OF M1 TO M2 MACROPHAGE POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS PERSPECTIVE"Abstract Number: 3752409Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsSession Type: Plenary SessionSession Title: Late-Breaking Basic Science Abstract PlenarySession Time: 2:00 PM to 3:30 PM PDT Presentation Time: 2:15 PM to 2:30 PM PDT May 23, 2022 Presentation Title: "ENRICHMENT OF PATIENTS WITH EHLERS DANLOS SYNDROME IN IDIOPATHIC GASTROPARESIS – A GENE SET ENRICHMENT ANALYSIS"Abstract Number: 3696881Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsSession Type: Poster SessionSession Title: Cell Biology, Biochemistry and Integrative PhysiologySession Time: 12:30 PM to 1:30 PM PDT For more information on DDW 2022, please refer to https://ddw.org/.

Vanda Pharmaceuticals Announces Presentations at DDW 2022

I am quite impressed with Vanda Pharmaceuticals' investing thesis. Though it cooled off recently, Vanda is still positing significant revenues that I expect would leap to a higher level either next year or beyond.

Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran – Senior Vice President & Chief Financial Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by.

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael H. Polymeropoulos on Q1 2022 Results - Earnings Call Transcript

WASHINGTON , May 5, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022. "We are excited with our progress in improving patient access for HETLIOZ®, especially for Medicaid beneficiaries with Non-24 and SMS diagnoses," said Mihael H.

Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results

WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022. A corporate presentation is scheduled for 4:00 p.m.

Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference

Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Thursday, May 5, 2022, during which management will discuss the first quarter 2022 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline

Amid the biotech bear market, many fundamentally sound companies are trading at a fraction of their intrinsic value.

Vanda: A Dual Growth And Value Player

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results - Earnings Call Transcript

WASHINGTON, Feb. 23, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2021. "We are proud of the progress we have made this past year with our existing products and in bringing HETLIOZ® to patients with Smith-Magenis Syndrome, leading to a strong financial performance, even in the face of extraordinary challenges," said Mihael H.

News for Vanda Pharmaceuticals Stock (VNDA)